IRIDEX Corporation, a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, has announced that it has received its CE Mark to commercialise across Europe.
The Cyclo G6 laser system is dedicated specifically to treat patients diagnosed with a range of glaucoma disease states and features the company's proprietary Micropulse® tissue-sparing technology and family of single use probes that connect to an intuitive, user-friendly laser console.
"This reglulatory approval marks a milestone for the glaucoma community and strengthens our portfolio to treat patients with difficult glaucoma conditions who need fast relief from uncontrolled eye pressure...Some studies of the Cyclo G6 have shown a 30-40% reduction in intraocular pressure (IOP) so this is a very promising therapy for our patients. In addition, the ability to reduce IOP without incisions nor using implants in a quick procedure is very attractive, as is the repeatability, potentially extending the time before more invasive measures are required." - Keith Barton, Consultant Ophthalmologist, Glaucoma service, Moorfields Eye Hospital.
The Cyclo G6 laser system is dedicated specifically to treat patients diagnosed with a range of glaucoma disease states and features Micropulse® tissue-sparing technology.View product details